6 Nov 2019 12:00
Summit Therapeutics to Participate in Panel Sessions at the World Antimicrobial Resistance Congress
Summit Therapeutics plc (‘Summit’ or the ‘Company’)
Summit Therapeutics to Participate in Panel Sessions at the World Antimicrobial Resistance Congress
Oxford, UK, and Cambridge, MA, US, 6 November 2019 – Summit Therapeutics plc (NASDAQ: SMMT, AIM: SUMM) announces that management will participate in two panel sessions at the World Antimicrobial Resistance Congress, taking place 7-8 November 2019 in Washington, DC.
In the panel sessions, Dr David Roblin, Chief Operating Officer and President of R&D, Dr Richard Vickers, Chief Scientific Officer, and Dr David Powell, Head of Research, will highlight the potential benefits of developing new mechanistic classes of precision antibiotics, including potency against resistant and non-resistant bacteria with minimal disturbance to the gut microbiome. This supports the principles of antibiotic stewardship.
Details of the sessions:Date: 7 November 2019Time: 2:10pm ESTSession: Roundtable 3 Innovation & Stewardship – Advancing narrow spectrum, new mechanism antibiotics as precision agents to by-pass resistance and to support antibiotic stewardship
Date: 8 November 2019Time: 1:00pm ESTSession: C-Suite Keynote Panel: Balancing continued innovation in R&D while navigating funding, stewardship and the overall commercial landscape
About Summit Therapeutics Summit Therapeutics is a leader in antibiotic innovation. Our new mechanism antibiotics are designed to become the new standards of care for the benefit of patients and create value for payors and healthcare providers. We are currently developing new mechanism antibiotics for infections caused by C. difficile, N. gonorrhoeae and Enterobacteriaceae and are using our proprietary Discuva Platform to expand our pipeline. For more information, visit www.summitplc.com and follow us on Twitter @summitplc.
Contacts
| Summit | ||
| Glyn Edwards / Richard Pye (UK office) | Tel: | 44 (0)1235 443 951 |
| Michelle Avery (US office) | +1 617 225 4455 | |
| Cairn Financial Advisers LLP (Nominated Adviser) | Tel: | +44 (0)20 7213 0880 |
| Liam Murray / Tony Rawlinson | ||
| N+1 Singer (Joint Broker) | Tel: | +44 (0)20 7496 3000 |
| Aubrey Powell / Jen Boorer, Corporate FinanceTom Salvesen, Corporate Broking | ||
| Bryan Garnier & Co Limited (Joint Broker) | Tel: | +44 (0)20 7332 2500 |
| Phil Walker / Dominic Wilson | ||
| MSL Group (US) | Tel: | +1 781 684 6652 |
| Erin Anthoine | summit@mslgroup.com | |
| Consilium Strategic Communications (UK) | Tel: | +44 (0)20 3709 5700 |
| Mary-Jane Elliott / Sue Stuart / Sukaina Virji | summit@consilium-comms.com | |
| Lindsey Neville |
-END-
SUMM.L (SUMM)